IPCA Laboratories (IPCALAB.NS) Stock Price

IPCA Laboratories Price

NSE·CLOSED
1,922.80
​
Market closed

Revenue has compounded at 13.1% per year over the past 19 years to 95.63 B INR. Earnings per share have grown at 12.2% per year over the last 19 years. IPCA Laboratories's net margin stands at 11.9%, down from 15.2% several years earlier. IPCA Laboratories currently offers a dividend yield of about 0.10%. The payout ratio is around 12% of earnings. The dividend has grown at 5.3% per year over the past 19 years. Analysts set a median price target of 1,632.00 INR, implying 15.1% below the current price. Of 20 analysts, 16 rate the stock a buy — an overall Buy consensus.

IPCA Laboratories stock price

Access this data via the Eulerpool API

IPCA Laboratories business model & stock analysis

Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,167 full-time employees. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.

Frequently asked questions about IPCA Laboratories

Analysts currently set an average price target of 1,612.89 INR for the IPCA Laboratories stock (median: 1,632.00 INR), implying -16.1 % versus the latest price. The consensus is based on 20 analyst ratings.

20 analysts currently rate the IPCA Laboratories stock: 16 recommend buying, 3 holding and 1 selling.

Converted at the current exchange rate, the IPCA Laboratories share trades at 17.74 EUR (1,922.80 INR).

The IPCA Laboratories share (IPCALAB.NS) is listed on 2 stock exchanges, including: NSE (Indien) (IPCALAB.NS).

The revenue of IPCA Laboratories is 95.63 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of IPCA Laboratories is 11.41 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of IPCA Laboratories is currently 42.75. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IPCA Laboratories stock.

The price-to-sales ratio (P/S) of IPCA Laboratories is currently 5.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IPCA Laboratories stock.

The Eulerpool Quality Score for IPCA Laboratories is 8/10.

The ISIN of IPCA Laboratories is INE571A01038. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of IPCA Laboratories is IPCALAB.NS. The ticker symbol is used to trade IPCA Laboratories shares on the stock exchange.

Fair ValueTerminal
1,845.89 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
5.91 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website ipca.com
Country
Currency
INR
Initial public offering
Feb 23, 1994
ISIN
INE571A01038
Cusip
Y4175R161
Market capitalization
487.81 B INRMega Cap
52-Week Range
PEG
4.05
P/E ratio
P/Ee 2027
32.05
P/Ee 2028
27.39
P/Ee 2029
23.71
P/S
P/Se
4.43
EV/EBIT
29.72
P/B Ratio
6.05
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
13.96 %
Dividend
Dividend yield
0.10 %
Est. Dividend Yield
0.62 %
Payout Ratio
12.06 %
Dividend growth Ø5Y
-21.00 %
Dividend payments per year
1
Dividend paid since
9 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
20.00 %
Last updated Oct 9, 2026, 7:34 PM

IPCA Laboratories Peer Group

IPCA Laboratories Ticker

BSE · IPCALAB.BONSE INDIA · IPCALAB.NS

IPCA Laboratories FIGI

IPCA:IN · BBG000D4LPY0IPCA:IB · BBG000D4LQN0IPCA:IS · BBG000D4LR21IPCA:IG · BBG003NVYQ40